Prior Western blotting experiments confirmed that FC101 simultaneously inhibits the activity of the MAPK pathway (corresponding to p-ERK reduction) and the mTOR pathway (corresponding to p-S6K and p-S6 reduction) in MAPK-driven TNBC cancer cells (Supplementary Materials). This evidence concerns the gene RPS6KB1 and cancer.